Fields Noelle L, Xu Ling, Williams Ishan C, Gaugler Joseph E, Cipher Daisha J
School of Social Work, University of Texas at Arlington, Arlington, TX, United States.
School of Nursing, University of Virginia, Charlottesville, VA, United States.
JMIR Res Protoc. 2023 Jul 24;12:e49679. doi: 10.2196/49679.
Alzheimer disease and related dementias (ADRD) pose significant challenges as chronic health conditions in the United States. Additionally, there are notable disparities in the diagnosis and prevalence of ADRD among diverse populations. Specifically, African American populations have a higher risk of developing late-onset ADRD than White people, and missed diagnoses of ADRD are more common among older African American populations than older White populations. These disparities also impact African American ADRD family caregivers.
The overall goal of this project is to develop a culturally informed, lay provider psychoeducational intervention named Senior Companion Program Plus (SCP Plus), which is specifically designed for African American ADRD caregivers and is potentially accessible, affordable, and sustainable.
In the proposed explanatory sequential mixed methods study, a randomized controlled trial will be used that includes 114 African American family caregivers of a relative with ADRD who will participate in the 3-month SCP Plus program.
The study was funded on September 15, 2018, by the National Institutes of Health (1R15AG058182-01A1). Data collection began on May 16, 2019, but due to COVID-19 restrictions, ended 12 months into the planned 27-month recruitment period on March 31, 2023. The study was completed in June 30, 2023, and currently the results are being analyzed.
The SCP Plus offers promise as an intervention that utilizes an existing platform for the delivery of a lay provider intervention and offers a novel approach for addressing gaps in accessible, community-based support for caregivers of people with ADRD.
ClinicalTrials.gov NCT03602391; https://classic.clinicaltrials.gov/ct2/show/NCT03602391.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR1-10.2196/49679.
在美国，阿尔茨海默病及相关痴呆症（ADRD）作为慢性健康状况构成了重大挑战。此外，ADRD在不同人群中的诊断和患病率存在显著差异。具体而言，非裔美国人患迟发性ADRD的风险高于白人，而且ADRD的漏诊在老年非裔美国人中比老年白人中更为常见。这些差异也影响着非裔美国人ADRD家庭护理人员。
本项目的总体目标是开发一种名为“高级陪伴计划升级版”（SCP Plus）的具有文化针对性的非专业护理人员心理教育干预措施，该措施专为非裔美国人ADRD护理人员设计，具有潜在的可及性、可承受性和可持续性。
在拟议的解释性序列混合方法研究中，将采用随机对照试验，其中包括114名患有ADRD亲属的非裔美国家庭护理人员，他们将参加为期3个月的SCP Plus计划。
该研究于2018年9月15日获得美国国立卫生研究院资助（1R15AG058182 - 01A1）。数据收集于2019年5月16日开始，但由于新冠疫情限制，在计划的27个月招募期进行到12个月时于2023年3月31日结束。该研究于2023年6月30日完成，目前正在分析结果。
SCP Plus作为一种干预措施具有前景，它利用现有的平台提供非专业护理人员干预，并为解决ADRD患者护理人员在可及的社区支持方面的差距提供了一种新方法。
ClinicalTrials.gov NCT03602391；https://classic.clinicaltrials.gov/ct2/show/NCT03602391。
国际注册报告识别码（IRRID）：RR1 - 10.2196/49679。
